Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG + N-803 in BCG-unresponsive high-grade non-muscle invasive bladder cancer
NCT03022825Phase 3Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 2017
- Primary completion
- Oct 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of nogapendekin alfa inbakicept in bladder cancer, sponsored by ImmunityBio, Inc.. Started Jun 2017; status: active, not recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03022825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022825.